At Aiolos Bio, we are dedicated to revolutionizing the treatment landscape for respiratory disease and other immune conditions. We’re on a mission to reimagine therapies that bring hope and relief to patients and caregivers alike.
Aiolos Bio is an accomplished team of seasoned drug developers with decades of industry experience and operational leadership. With over 30 FDA approvals, we’ve successfully developed and launched products for a range of immune conditions, including asthma, rheumatoid arthritis, IPF, and more.
Our vision is embodied in our current focus – the development of a groundbreaking anti-TSLP asset. This asset boasts the potential of impressive efficacy and a dramatically less frequent dosing schedule compared to current standard of care. Our ultimate goal is to provide patients and caregivers with more efficacious therapies that significantly reduce treatment burden.
Co-Founder and Chief Executive Officer
Jane Hughes, PhD
Chief Scientific Officer
Chief Technical Officer
Chris Clevenger, PhD
SVP, Clinical Operations
Head, Regulatory Strategy
VP, Life Cycle Management
VP, Corporate Strategy and Operations
VP, Commercial Strategy and Operations
Board of Directors
John F. Milligan, PhD
Chairman of the Board
Tony Adamis, MD
Co-Founder and Board Member
Co-Founder and Chief Executive Officer
Partner, Atlas Venture
General Partner, Forbion
Maha Katabi, PhD
General Partner, Sofinnova Investments
Amir Zamani, MD
Managing Director, Bain Capital Life Sciences
In the News
- October 24, 2023: ENDPOINTS NEWS
Aiolos Bio launches with $245M Series A, chasing one of asthma’s hottest targets
- October 24, 2023: STAT News
Startup launches with $245 million for twice yearly asthma treatment
- October 24, 2023: Timmerman Report
Aiolos Bio, With $245M from Atlas, Bain, Aims at TSLP for Asthma
- October 24, 2023: FIERCE Biotech
Aiolos Bio launches with ex-Gyroscope CEO at the helm, nearly $250M to advance severe asthma med
OUR FIRST ASSET:
AIO-001 is a monoclonal antibody which specifically targets and blocks TSLP, a validated driver of inflammation in diseases like asthma. TSLP inhibition is the only biological approach that has demonstrated clinical benefit for patients with all forms of moderate-to-severe asthma.
AIO-001 has demonstrated high potency and an extended half-life in pre-clinical studies and initial clinical trials. AIO-001’s unique properties allow investigation in clinical trials as a therapy that only needs to be administered every six months. With the convenience of biannual dosing, patients can focus less on managing asthma and more on living life to the fullest, reducing the impact of asthma on their daily lives.
ABOUT MODERATE-TO-SEVERE ASTHMA
Asthma presents a significant and growing global health challenge, impacting more than 260 million individuals worldwide and contributing to over 450,000 annual deaths.1 In the United States, this respiratory condition affects a staggering 25 million people, nearly 8% of the total population.2 Despite the use of inhaled corticosteroids (ICS), a significant proportion of individuals continue to grapple with uncontrolled asthma symptoms. Notably, a subset of patients, approximately 5%-10%, falls under the category of severe asthma,3-6 which remains uncontrolled even with optimized high-dose ICS treatment or worsens when high-dose treatment is reduced.
- Global Burden of Disease Study 2019, The Lancet. 2020;396(10258):1204-22.
- CDC National Center for Health Statistics, National Health Interview Survey (NHIS). National Surveillance of Asthma: United States, 2001–2021.
- Rönnebjerg L, Axelsson M, Kankaanranta H, Backman H, Rådinger M, Lundbäck B, Ekerljung L. Severe Asthma in a General Population Study: Prevalence and Clinical Characteristics. J Asthma Allergy. 2021 Sep 16;14:1105-1115. Doi: 10.2147/JAA.S327659. PMID: 34556999; PMCID: PMC8454418.
- Backman H, Jansson SA, Stridsman C, Eriksson B, Hedman L, Eklund BM, Sandström T, Lindberg A, Lundbäck B, Rönmark E. Severe asthma-A population study perspective. Clin Exp Allergy. 2019 Jun;49(6):819-828. Doi: 10.1111/cea.13378. PMID: 30817038.
- Von Bulow A, Kriegbaum M, Backer V, Porsbjerg C. The prevalence of severe asthma and low asthma control among Danish adults. J Allergy Clin Immunol Pract. 2014;2(6):759–767. Doi: 10.1016/j.jaip.2014.05.005.
- Hekking PW, Wener RR, Amelink M, Zwinderman AH, Bouvy ML, Bel EH. The prevalence of severe refractory asthma. J Allergy Clin Immunol. 2015;135(4):896–902. Doi: 10.1016/j.jaci.2014.08.042.
Do you have questions or want to learn more about our transformative work? Reach out to us using the form here. We value your input and are excited to engage with like-minded individuals, potential partners, and collaborators who share our passion for innovation in respiratory and inflammatory disease research.